Combination of the DOPA decarboxylase inhibitor carbidopa and levodopa used since the early 1970's for the treatment of Parkinsons disease. The original 1:10 ratio developed when levodopa was the only real competitor, admittedly briefly, was shown to be incorrect in most clinical practice by the end of the 1970s and the 1:4 ratio should be used at the lower doses used in initiation of therapy and is regarded by most as therapeutically equivalent to co-beneldopa at equivalent levodopa dose.
- ↑ Rinne UK, Mölsä P. Levodopa with benserazide or carbidopa in Parkinson disease. Neurology. 1979 Dec; 29(12):1584-1589.(Print) (Link to article – subscription may be required.)
- ↑ Streifler M, Vardi J, Kesten M. Treatment of parkinsonism with L-dopa and an L-aromatic amino acid inhibitor. Harefuah. 1972 Nov; 83(9):362-364.(Print)
- ↑ Pakkenberg H, Birket-Smith E, Dupont E, Hansen E, Mikkelsen B, Presthus J, Rautakorpi I, Riman E, Rinne UK. Parkinson's disease treated with Sinemet or Madopar. A controlled multicenter trial. Acta neurologica Scandinavica. 1976 May; 53(5):376-385.(Print) (Link to article – subscription may be required.)
- ↑ Greenacre JK, Coxon A, Petrie A, Reid JL. Comparison of levodopa with carbidopa or benserazide in parkinsonism. Lancet (London, England). 1976 Aug; 2(7982):381-384.(Print) (Link to article – subscription may be required.)